In Naples, today December 5th and tomorrow, the important scientific meeting "Hot Topics on Sarcomas: Precision, Proximity, ...

Truist analyst Karina Rabayeva initiated coverage of Immunome (IMNM) with a Buy rating and $36 price target The company’s lead asset, ...

Patients with desmoid tumors face significant clinical and economic burdens, impacting their quality of life and leading to ...

The price target increase reflects Stephens’ strengthened conviction in the longer-term potential of Immunome’s varegacestat treatment for desmoid tumors, which is expected to present top-line data ...

FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced that the U.S. Food and Drug Administration ...

Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial In the phase III ...

Sporadic intraabdominal desmoid tumor is a rare occurrence, comprising 0.03% of all neoplasms. It has an estimated incidence of 2 to 4 per million in the general population. Only 15% of all desmoid ...

Desmoid tumors are malignant non-inflammatory fibroblastic tumors with a tendency for local invasion and recurrence post resection. They are considered a locally aggressive proliferative disease ...

INDIANAPOLIS (WISH) — Elevate the Stage, a benefit concert for Elevate Childhood Cancer Research and Advocacy, is set to take place on September 5 at The Commons in Columbus, Indiana, featuring ...